Slide 1: Q2 2025 results
Q2 2025 results Continued strong D portfolio and pipeline momentum Conference call and webcast for analysts and investors 16 July 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Conference call agenda
Conference call agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 3
Slide 4: Q2 Highlights: Growth, Portfolio Expansion & Pipeline Milestones
Q2 Highlights: Growth, Portfolio Expansion & Pipeline Milestones Continued Portfolio growth, +22% at CER Revenue Q2: SEK 6,175 M, +22% Adjusted EBITA margin Q2: 34% Strategic portfolio1 accounts for 55% of revenue in the quarter - growing 65% at CER • Altuvoct® SEK 627 M • Gamifant® SEK 632 M, +33%
Slide 5: Delivering strong Q2 growth & advancing long-term value
Delivering strong Q2 growth & advancing long-term value Underpinned by robust portfolio performance and global delivery Revenue by segment Revenue by region Q2 2025 change contrib. Q2 2025 change SEK M % % SEK M % Haematology 4,570 +27 74 Europe 2,626 +21 – Haemophilia 2,699 +24 43 North America 2,1
Slide 6: Strong momentum across the portfolio in Q2
Strong momentum across the portfolio in Q2 Second quarter 2025 Haematology • Haemophilia A sales: Growing 32% driven by robust Elocta 991 -18% Altuvoct launch Altuvoct 627 >200% Alprolix 565 +7% • Doptelet: Continued strong demand across markets Altuviiio royalty 248 +98% with 43% growth Other Haem
Slide 7: Altuvoct: Launches continue in Europe and Middle East
Altuvoct: Launches continue in Europe and Middle East Haemophilia A sales (Altuvoct +Elocta) grew 32% in Q2 Haemophilia A sales SEK 1,618 M +32% Q2 Altuvoct launch: • Second quarter 2025 sales of SEK 627 M • Strong launch progress with initial sales in 17 countries led by Germany, Switzerland, and S
Slide 8: Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026
Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026 Aspaveli/Empaveli SEK 304 M +28% Q2 PNH • Continued growth across markets with strong YoY growth, competitive pressure in PNH growing in Europe Nephrology* • EU: CHMP opinion expected by end 2025 • Best in class
Slide 9: Vonjo: Demand growing but sales impact from gross to net adjustments
Vonjo: Demand growing but sales impact from gross to net adjustments Vonjo SEK 302 M -4% Q2 • Demand increasing vs PY in Q2: +11% volume growth • Net sales -4% in Q2 • GTN impact due to recent changes in reimbursement Strategic progress: (Focus: label expansion, guideline support, Internationalizati
Slide 10: Gamifant: US FDA approves MAS in Still's disease
Gamifant: US FDA approves MAS in Still’s disease Strong sales growth driven by an increase in the number of patients on treatment and positive patient mix Gamifant SEK 632 M +33% Q2 FDA approves, after priority review Gamifant as first-ever treatment for adults and children with Macrophage Activatio
Slide 11: Sobi's near term building block of the future
Sobi’s near term building block of the future Investment in 2025 for multiple launches in 2025/26 2 3 4 Major launches Key filings Priority development projects in area of high 1. Altuvoct 1. Gamifant - HLH/MAS unmet medical need 2. Vonjo 2. Aspaveli - C3G/IC- MPGN 1. Gamifant - IDS 3. NASP - unco
Slide 12: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 12
Slide 13: Q2 2025 Revenue and profit & loss
Q2 2025 Revenue and profit & loss Q2 Q2 Full-year Total revenue (SEK M) Amounts in SEK M 2025 2024 Change 2024 Total revenue 6,175 5,442 13% 26,027 Haematology Immunology Specialty Care Adjusted Gross profit 1,2 4,781 4,166 15% 20,326 7 436 6 894 385 Adjusted Gross margin 1,2 77% 77% 78% 6 465 311 6
Slide 14: Organisational update to maximise future potential and setup for success
Organisational update to maximise future potential and setup for success Key priorities Organisation fit for purpose 2 3 4 Major launches Key filings Priority development projects in area of high 1. Altuvoct 1. Gamifant - unmet medical need Optimised way of 2. Vonjo HLH/MAS working 2. Aspaveli - C3G
Slide 15: Sobi Outlook 2025
Sobi Outlook 2025 Key considerations for 2025 2025 outlook • Altuvoct launch progress Revenue • Continued progress with commercial portfolio Anticipated to grow by a high single- • Beyfortus royalty digit percentage at CER • Launch preparation • In US for NASP in uncontrolled gout • In Europe for As
Slide 16: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 16
Slide 17: Solid pipeline progress in Q2 2025
Solid pipeline progress in Q2 2025 C3G and IC-MPGN Aspaveli/ VALIANT 52-week: consistent efficacy & safety Empaveli TA-TMA Discontinued after Phase 2 strategic review HLH/MAS in Still’s disease Gamifant FDA approved extended indication Uncontrolled gout NASP FDA rolling submission completed VEXAS Vo
Slide 18: VALIANT (26 weeks): consistent efficacy of pegcetacoplan in key populations
VALIANT (26 weeks): consistent efficacy of pegcetacoplan in key populations Overall Nephrotic Concomitant Adolescents population range immunosuppression UPCR ≥3 g/g 12-17 years 0% Proteinuria % reduction -68% -72% -70% -75% reduction 50% vs placebo 100% 20 mL/min/1.73 m2 eGFR stabilisation / 15 impr
Slide 19: With 1 year of treatment, pegcetacoplan led to robust and sustained proteinuria reductions
With 1 year of treatment, pegcetacoplan led to robust and sustained proteinuria reductions and stable eGFR for patients with C3G and primary IC-MPGN VALIANT study in Proteinuria reduction: patients aged ≥12 years with native 67% reduction in patients receiving 52 weeks of pegcetacoplan or post-trans
Slide 20: Progress to be continued in 2025-26
Progress to be continued in 2025-26 Anticipated pipeline news flow 2025 H2 2026 Aspaveli – C3G & IC-MPGN Aspaveli – C3G & IC-MPGN o EU CHMP opinion o EU regulatory decision o Japan regulatory submission o Japan regulatory decision Gamifant – HLH / MAS in Still’s disease Gamifant – HLH / MAS in Still
Slide 21: Agenda
Agenda Business update Guido Oelkers, Chief Executive Officer Financials Henrik Stenqvist, Chief Financial Officer R&D Pipeline Lydia Abad-Franch, Head of R&D and Chief Medical Officer Summary and Q&A 21
Slide 22: Strong business development and pipeline progress
Strong business development and pipeline progress Preparing the organisation to unlock potential and drive future success % growth at CER Revenue Q2: SEK 6,175 M, +22% : Year to date +12% Significant growth Third consecutive year as Adjusted EBITA margin Q2: 34% constituent of the Dow Jones Best-in-
Slide 23: Q&A
Q&A 23
Slide 24: Current Development Pipeline
Current Development Pipeline Major ongoing clinical studies and medicines in registration in a major region or country Phase 2 Phase 3 Registration Vonjo® (pacritinib) Vonjo® (pacritinib) Aspaveli®(pegcetacoplan) VEXAS (Vacuoles, E1 enzyme, X-linked, Myelofibrosis with severe C3G & primary IC-MPGN a
Slide 25: Appendix: Q2 2025 sustainability performance
Appendix: Q2 2025 sustainability performance Highlights in Q2 2025 Sobi sustainability priorities Third consecutive year as • Awareness and patient support member of DJSI Europe, now - Announced second renewal of Maintain commitment to Always act responsibly renamed DJ Best-in-Class Europe collabora
Slide 26: Thank you
CONFIDENTIAL – FOR INTERNAL USE ONLY Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com